Understand which supplements actually match your bloodwork
Review a real sample panel or analyze your own labs to see which markers matter, what surfaced first, and where to go deeper next.
Berberine
Insulin resistance support with lipid and hepatic signal overlap.
Most useful when fasting glucose, HbA1c, triglycerides, and ApoB pattern together as metabolic risk rather than isolated noise.
Pairing glucose-lowering compounds without dose sequencing can exaggerate hypoglycemic risk and blur interpretation on retest.
Start with the biomarker signal, then go deeper only when it matters.
The first job is clarity. Once a marker needs action, the rest of the system becomes the supporting layer around that decision.
01
Review a real panel
Start with your own labs or a public sample panel so the product can anchor interpretation to actual biomarker values.
02
See what matters and why
Flagged markers are prioritized by urgency, evidence-backed direction, and the reasoning behind what surfaced first.
03
Move into research or protocol logic
Use the same signal to open dossiers, compare options, and turn the strongest directions into a next-step plan.
A public case that shows what the product actually does.
This preview uses the same interpretation layer as the gated product flow, built around one LDL-C-led sample panel.
Sample panel
Sample cardiometabolic review
A focused demo case built from the real Analyze interpretation layer. LDL-C is the main out-of-range signal, with companion markers included for context.
LDL
LDL Cholesterol
170
mg/dL
HDL
HDL Cholesterol
52
mg/dL
TG
Triglycerides
118
mg/dL
Glucose
Fasting Glucose
92
mg/dL
Flagged summary
LDL needs intervention
LDL is 70% above 100 mg/dL at 170 mg/dL.
Surfaced direction
Magnesium
Chosen because indexed human evidence maps it to lowering LDL, and lDL C: small - MA_RCT - dyslipidemic, cardiometabolic_risk.
Safety watch-out
LDL C: small - adult, dyslipidemia, hypertriglyceridemia.
Go deeper once a marker needs action
Start with a clear biomarker signal, then use research, compare, protocol, and follow-through as the supporting layers around that decision.
Research Library
Move from the flagged marker into searchable compound, lifestyle, and drug dossiers with biomarker context attached.
Dossier Detail
Open the evidence table, mechanism framing, dosing detail, and cautions behind the direction that surfaced.
Compare
Place the strongest options side by side once you know which marker pattern deserves the next review.
Protocol Builder
Turn the strongest directions into a timing-aware stack once the biomarker case is clear.
Interaction Check
Review compound-compound and compound-drug conflicts before a promising idea becomes a contradictory stack.
Follow-through
Track whether the marker moves in the right direction after the protocol changes.
Longitudinal Tracking
Follow biomarkers, protocol changes, and retest timing over time so analysis does not end at one panel.
Review the sample caseThe trust layer is built into the product, not hidden behind marketing copy
Dossiers are built through an explicit research pipeline. Evidence quality, replication, conflicts, biomarker linkage, and interaction logic are visible because they change the recommendation itself.
Grades reflect study quality, replication, and relevance to the actual claim rather than abstract positivity.
Literature sweep
PubMed, meta-analyses, trial registries, and mechanistic papers are reviewed before a dossier is assembled.
Evidence grading
Claims are graded A-D by study quality, replication, population fit, and clinical relevance.
COI screening
Industry funding and author conflicts are flagged so the evidence base is visible, not hidden.
Biomarker mapping
Effects are mapped to concrete markers, directionality, dose context, and expected timing.
PGx review
Relevant genomic modifiers are separated into actionable signals versus exploratory context.
Interaction network
Compound-compound and compound-drug conflicts are screened before protocol logic is exposed.
Clinical structuring
Dosing, safety, evidence, and watch-outs are rewritten into a decision-oriented brief rather than a study dump.
Continuous updates
As evidence shifts, dossiers, triage signals, and recommendations can be updated without rewriting the system.
Clear tiers for research-first users and full analysis workflows
Start with dossiers and evidence. Upgrade when you need bloodwork triage, personalized recommendations, protocol logic, and ongoing tracking.
Cancel anytime. Use billing management to change plan, payment method, or cancellation status.
“We built this because serious supplement decisions still require too much tab-hopping, too much guesswork, and too little biomarker context.”
The goal is simple: take dense research, expose the evidence quality, connect it to biomarkers, and make the next action obvious enough to use in real decisions.